This human clinical study evaluated hydromethylthionine (a formulation of methylene blue) as a potential therapeutic agent for Alzheimer’s disease, examining its pharmacological properties and clinical efficacy based on available evidence. The research assessed hydromethylthionine’s mechanism of action, safety profile, and effectiveness in slowing cognitive decline in Alzheimer’s patients, contributing to the expert analysis of its role among treatment options. This evidence represents human clinical research on a pharmaceutical intervention for neurodegenerative disease.